A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 87
Summary
- Conditions
- Basal Cell Carcinoma
- Breast Carcinoma
- Castration-Resistant Prostate Carcinoma
- Non-squamous Cell Salivary Gland Carcinoma
- Neuroendocrine Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Thymoma
- Cervical Cancer
- Small Cell Lung Carcinoma
- Vulvar Carcinoma
- Cholangiocarcinoma
- Non Small Cell Lung Carcinoma
- Melanoma
- Urothelial Carcinoma
- Colorectal Carcinoma
- Endometrial Carcinoma
- Squamous Cell Carcinoma of the Penis
- Fallopian Tube Carcinoma
- Nasopharyngeal Carcinoma
- Squamous Cell Carcinoma of the Anus
- Ovarian Carcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Hepatocellular Carcinoma
- Malignant Adnexal Neoplasms
- Thymic Carcinoma
- Renal Cell Carcinoma
- Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
- Mesothelioma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03517488
- Collaborators
- ICON plc
- Investigators
- Study Director: Barbara Hickingbottom, MD Xencor, Inc.
Get Well Soon